english.prescrire.org > Prescrire International > N°170 - April 2016

n°170

April 2016

Issue Contents
Editorial

Free  The key is in the name

p.88
International nonproprietary names are meaningful; brand names are not

New Products


Ibrutinib (Imbruvica°)

p.89-92
Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival

INN Common stem: -terol

p.92

Cholic acid (Kolbam°)

p.93
An advance in very rare hereditary bile acid synthesis defects

Vilanterol + fluticasone (Relvar Ellipta°)

p.94
Asthma and COPD: yet another beta-2 agonist and corticosteroid combination

Olodaterol (Striverdi Respimat°)

p.95
COPD: just another beta-2 agonist

Adverse Effects


Venlafaxine: more dangerous than most "selective" serotonergic antidepressants

p.96-99
Harms have been expected and are confirmed

Citalopram, escitalopram: no more effective than other SSRIs, but more toxic

p.98

Crizotinib: heart failure

p.99
A growing list of adverse effects

Free  SSRI antidepressants: extrapyramidal reactions

p.100
Following drug introduction or dose increase

Free  Mirabegron: hypertension, stroke

p.100
A poor option in urinary incontinence

Free  Gliptins: disabling joint pain

p.100
Poor harm-benefit balance

Reviews


Allergic rhinitis during pregnancy

p.101-104
Oral non-sedating antihistamines without antimuscarinic effects

Drugs to avoid in pregnant women with allergies

p.103

Outlook


Free  Towards better patient care: drugs to avoid in 2016

p.105-111
Notable changes in the 2016 update: citalopram, escitalopram, diclofenac added to the list of drugs to avoid

Free  Notable changes in the 2016 update: citalopram, escitalopram, diclofenac added to the list of drugs to avoid

p.107

Masthead


Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe